- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00142454
NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)
NY-ESO-1 Protein Vaccination in Malignant Melanoma Administered With Imiquimod as Adjuvant
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Patients applied imiquimod (250 mg) topically to a designated area of healthy skin on the upper inner arm or inner thigh (the cream remained on the skin overnight for 6-10 hours) every day for 5 consecutive days (i.e., for the first 5 days of Cycles 1-3 and for the first 4 days of Cycle 4). The NY-ESO-1 protein (100 μg) was injected intradermally into the imiquimod-pretreated area on Day 3 of each cycle for 4 consecutive 21-day cycles.
Safety was monitored continuously. Immunization was assessed by the generation of NY-ESO-1-specific cluster of differentiation (CD)4+ and CD8+ T cell responses in enzyme-linked immunosorbent spot (ELISPOT) assays and by the development or augmentation of NY-ESO-1-specific antibody titers, assessed by enzyme-linked immunosorbent assay (ELISA).
Blood samples were obtained for the assessment of clinical biochemistry and hematology, and physical examinations were performed at baseline, on Day 1 of each cycle, and at a follow-up visit at Week 13.
Skin biopsies of the vaccinated area were obtained 48 hours after the last injection (Day 5 of Cycle 4). To avoid irritation, imiquimod was not applied after the biopsies.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
New York
-
New York, New York, Verenigde Staten, 10016
- NYU Cancer Institute
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Had histologically confirmed, resected American Joint Committee on Cancer Stage IIB, IIC or III malignant melanoma
- Fully recovered from surgery
- Age ≥ 18 years; children were excluded from this study, as the safety of imiquimod had not been established in patients below the age of 18
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
Adequate organ and marrow function as defined below:
- absolute neutrophil count: ≥ 1500/μL
- hemoglobin: ≥ 9 g/dL
- platelets: ≥ 100,000/μL
- total bilirubin: ≤ 1.5 × institutional upper limit of normal (ULN)
- aspartate aminotransferase/alanine aminotransferase (AST/ALT): ≤ 2.5 × institutional ULN
- creatinine: ≤ 1.5 × institutional ULN
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Received chemotherapy, immunotherapy (including interferon), or radiotherapy within 4 weeks prior to first dosing of study agent
- Prior treatment with NY-ESO-1 vaccines
- Known human immunodeficiency virus infection or autoimmune disease (rheumatoid arthritis, systemic lupus erythematosus), as these conditions could have interfered with the evaluation of the induced immune response; patients with vitiligo or melanoma-associated hypopigmentation were not excluded
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to imiquimod or other agents used in the study
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection,symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would have limited compliance with study requirements
- Pregnancy or lactation
- Women of childbearing potential not using a medically acceptable means of contraception
- Known history of inflammatory skin disorders, as imiquimod might have exacerbated these conditions
- Chronic corticosteroid or immunosuppressive therapies, as these might have interfered with the evaluation of the induced immune response
- Lack of availability for immunological and clinical follow-up assessments
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Imiquimod + NY-ESO-1
Patients applied topical imiquimod followed by vaccination with intradermal injections of the NY-ESO-1 protein.
|
Patients applied imiquimod cream at bedtime every day for 5 consecutive days (for the first 5 days of Cycles 1-3 and for the first 4 days of Cycle 4) at a dose of 250 mg as supplied in single-use packets to a 4 x 5 cm area of healthy skin, alternating among the extremities (upper inner arms and inner thighs) in each cycle.
The cream was to be rubbed into the skin until it was no longer visible.
Patients were encouraged to wash their hands before and after applying cream.
The application site was not occluded.
The next morning, 6 to 10 hours after initial application, the treated area was washed with mild soap and water to remove any residual cream.
Andere namen:
NY-ESO-1 protein was injected intradermally by a study physician or nurse at a dose of 100 μg into the imiquimod-pretreated area on Day 3 of each cycle for 4 consecutive 21-day cycles.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Number of Patients With Treatment-emergent Adverse Events (TEAEs)
Tijdsspanne: Up to 4 months
|
Toxicity was graded in accordance with the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0, as follows: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (life-threatening), and Grade 5 (fatal).
Adverse events (AEs) were reported based on clinical laboratory tests, vital sign and weight measurements, physical examinations, performance status evaluations, and any other medically indicated assessments, including patient interviews, from the time informed consent was signed through the last follow-up visit.
AEs were considered to be treatment emergent (TEAE) if they occurred or worsened in severity after the first dose of study treatment.
|
Up to 4 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Number of Patients With Cellular Antibody Response to NY-ESO-1 at Two or More Post-vaccination Time Points
Tijdsspanne: Up to 4 months
|
Assays to assess cluster of differentiation (CD)8+ and CD4+ antigen-specific responses were performed at baseline (Cycle 1 Day 1), throughout the vaccination period (Day 1 of Cycles 2 through 4 and Day 10 of each cycle), and at the 2 post-treatment follow-up visits (Weeks 13 and 16) by enzyme-linked immune absorbent spot (ELISPOT) assay following prior in vitro sensitization.
A 3-fold increase in spot-forming cells over baseline defined a positive response.
Suitable antigens may have included recombinant viral vectors encoding NY-ESO-1, or NY-ESO-1 overlapping peptides, depending upon availability.
|
Up to 4 months
|
Number of Patients With Humoral Antibody Response to NY-ESO-1
Tijdsspanne: Up to 4 months
|
Assays to assess NY-ESO-1 specific antibodies were performed at baseline (Cycle 1 Day 1), throughout the vaccination period (Day 1 of Cycles 2 through 4 and Day 10 of each cycle), and at the 2 post-treatment follow-up visits (Weeks 13 and 16) by enzyme-linked immunosorbent assay (ELISA).
Samples were diluted serially.
The induction and augmentation of immunity were defined as an increase in antibody titer of ≥ 3× over buffer alone or ≥ 4× the pre-vaccination titer, respectively.
Sera from the responding patients were tested a second time against a pool of NY-ESO-1 overlapping peptides to confirm NY-ESO-1 specificity; the number of patients in the table reflect the patients with confirmed NY-ESO-1 specificity.
|
Up to 4 months
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Nina Bhardwaj, MD, PhD, NYU Langone Health
- Studie directeur: Sylvia Adams, MD, NYU Langone Health
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per histologisch type
- Neoplasmata
- Neuro-ectodermale tumoren
- Neoplasmata, kiemcellen en embryonaal
- Neoplasmata, zenuwweefsel
- Neuro-endocriene tumoren
- Nevi en melanomen
- Melanoma
- Fysiologische effecten van medicijnen
- Antineoplastische middelen
- Immunologische factoren
- Adjuvantia, immunologisch
- Interferon-inductoren
- Imiquimod
Andere studie-ID-nummers
- LUD2004-006
- NYU 04-53 (Andere identificatie: New York University)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Kwaadaardig melanoom
-
Istituto Clinico HumanitasWervingDISTALE MALIGNANT BILIAIRE OBSTRUCTIEItalië
-
National Taiwan University HospitalOnbekend
-
The Netherlands Cancer InstituteOnbekendStadium IV huidmelanoom | Oog; MelanomaNederland
-
University of AarhusDanish Cancer Society; AmbuFlexVoltooidMelanoma | Kwaliteit van het levenDenemarken
-
Herlev HospitalVoltooidMelanoma | HuidkankerDenemarken
-
Herlev HospitalVoltooidGeïntegreerde basiswetenschap binnen het instructieontwerp van patroonherkenningstraining (AISC-ISF)Melanoma | HuidkankerDenemarken
-
University Medical Center GroningenWervingMelanoma | Hoofd- en nekneoplasmata | MSI-H-kankerNederland
-
Vanderbilt-Ingram Cancer CenterWren Laboratories LLCVoltooidMelanomaVerenigde Staten
-
Mayo ClinicActief, niet wervendMelanoma | Borstkanker | LymfoedeemVerenigde Staten
-
University of UtahVoltooidMelanoma | JongvolwasseneVerenigde Staten
Klinische onderzoeken op Imiquimod
-
Graceway Pharmaceuticals, LLCVoltooidGenitale wrattenVerenigde Staten
-
Taro Pharmaceuticals USAVoltooid
-
Graceway Pharmaceuticals, LLCVoltooidGenitale wrattenVerenigde Staten
-
Graceway Pharmaceuticals, LLCVoltooid
-
Graceway Pharmaceuticals, LLCVoltooidOppervlakkig basaalcelcarcinoomAustralië, Nieuw-Zeeland
-
Graceway Pharmaceuticals, LLCVoltooidActinische keratoseVerenigde Staten
-
Teva Pharmaceuticals USAVoltooidActinische keratoseVerenigde Staten
-
Taro Pharmaceuticals USAVoltooid